AVEO garners $100M from stock offering; Report: iPierian shakeup continues; Qiagen buying Ipsogen;

@FierceBiotech: Cancer immunotherapies in vogue as specialists seek a "cure." Story | Follow @FierceBiotech

@JohnCFierce: NIH is handing out $200M to five institutions for translational med work. Item | Follow @JohnCFierce

> AVEO Pharmaceuticals says it will net slightly more than $100 million on its sale of 5.75 million discounted shares, much of which will be used for its ambitious R&D plans. The developer recently grabbed an impressive $125 million upfront from its partnership with Astellas on tivozanib, a promising experimental cancer drug. Story

Xconomy reports that the shakeup at iPierian is continuing with the departure of Corey Goodman, its high-profile chairman, and Harvard stem cell expert Doug Melton, a member of the advisory committee. Story

> Stemgent has reportedly now taken in $10.6 million of a $14.1 million Series B. Report

> Qiagen said today that it will acquire France's Ipsogen, a diagnostics company which it values at €70 million. Story

> Meda says it presented positive Phase III data on Dymista, a treatment for allergic rhinitis. Release

Pharma News

@FiercePharma: Laid-off Pfizer reps join OT lawsuit. News | Follow @FiercePharma

> Study: Pfizer, BI inhaler boosts death risk. Report

> Sanofi moves deeper into Genzyme operations. News

> Roche's Herceptin sensitivity test wins FDA nod. Story

> FDA warns Dr Reddy's on Mexico plant's shortfalls. Item

> NC lawsuit shield falters in legislature. Article

Drug Delivery News

> Pfizer, pSivida deal is about big market in patient compliance. Piece

> New delivery system gives Parkinson's patients better quality of life. Article

> Mist inhaler to treat lung disease may not be safe. Report

> UK company looks to move from nutraceuticals to pharmaceuticals. Story

> Nanoparticle delivery into inner ear may help hearing loss. Article

> Singapore scientists design hydrogels that react to pH, temperature. Item

Medical Device News

> Covidien to shake up management structure. News

> Cordis to rein in stent development, cut jobs. Item

> QIAGEN looks to buy Ipsogen. Report

> CerebralRx's FitNes system launched in Europe. Article

> Secant to work with Solvant on biomedical implants. Story

> Spinal Modulation snags $30M in Series D. Report

And Finally... Biotech entrepreneur John Crowley--whose fight to develop a new treatment for Pompe disease to help two of his children became the basis for the movie "Extraordinary Measures"--may run for a Senate seat in New Jersey. Story

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.